251 related articles for article (PubMed ID: 15692071)
1. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
Schimanski LM; Drakesmith H; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 May; 105(10):4096-102. PubMed ID: 15692071
[TBL] [Abstract][Full Text] [Related]
2. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
Drakesmith H; Schimanski LM; Ormerod E; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 Aug; 106(3):1092-7. PubMed ID: 15831700
[TBL] [Abstract][Full Text] [Related]
3. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
Détivaud L; Island ML; Jouanolle AM; Ropert M; Bardou-Jacquet E; Le Lan C; Mosser A; Leroyer P; Deugnier Y; David V; Brissot P; Loréal O
Hum Mutat; 2013 Nov; 34(11):1529-36. PubMed ID: 23943237
[TBL] [Abstract][Full Text] [Related]
4. Characterization of three novel pathogenic SLC40A1 mutations and genotype/phenotype correlations in 7 Italian families with type 4 hereditary hemochromatosis.
Majore S; Bonaccorsi di Patti MC; Valiante M; Polticelli F; Cortese A; Di Bartolomeo S; De Bernardo C; De Muro M; Faienza F; Radio FC; Grammatico P; Musci G
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):464-470. PubMed ID: 29154924
[TBL] [Abstract][Full Text] [Related]
5. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
Praschberger R; Schranz M; Griffiths WJ; Baumgartner N; Hermann M; Lomas DJ; Pietrangelo A; Cox TM; Vogel W; Zoller H
Biochim Biophys Acta; 2014 Sep; 1842(9):1406-12. PubMed ID: 24859227
[TBL] [Abstract][Full Text] [Related]
6. Impaired iron transport activity of ferroportin 1 in hereditary iron overload.
McGregor JA; Shayeghi M; Vulpe CD; Anderson GJ; Pietrangelo A; Simpson RJ; McKie AT
J Membr Biol; 2005 Jul; 206(1):3-7. PubMed ID: 16440176
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis of ferroportin-linked hemochromatosis.
De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
[TBL] [Abstract][Full Text] [Related]
8. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis of hepcidin-resistant hereditary hemochromatosis.
Fernandes A; Preza GC; Phung Y; De Domenico I; Kaplan J; Ganz T; Nemeth E
Blood; 2009 Jul; 114(2):437-43. PubMed ID: 19383972
[TBL] [Abstract][Full Text] [Related]
10. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
Rishi G; Secondes ES; Wallace DF; Subramaniam VN
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
[TBL] [Abstract][Full Text] [Related]
11. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype.
Wallace DF; Harris JM; Subramaniam VN
Am J Physiol Cell Physiol; 2010 Jan; 298(1):C75-84. PubMed ID: 19846751
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation.
Griffiths WJ; Mayr R; McFarlane I; Hermann M; Halsall DJ; Zoller H; Cox TM
Hepatology; 2010 Mar; 51(3):788-95. PubMed ID: 19937651
[TBL] [Abstract][Full Text] [Related]
14. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.
Mayr R; Janecke AR; Schranz M; Griffiths WJ; Vogel W; Pietrangelo A; Zoller H
J Hepatol; 2010 Nov; 53(5):941-9. PubMed ID: 20691492
[TBL] [Abstract][Full Text] [Related]
15. Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.
Viveiros A; Panzer M; Baumgartner N; Schaefer B; Finkenstedt A; Henninger B; Theurl I; Nachbaur K; Weiss G; Haubner R; Decristoforo C; Tilg H; Zoller H
Liver Int; 2020 Aug; 40(8):1941-1951. PubMed ID: 32450003
[TBL] [Abstract][Full Text] [Related]
16. Ferroportin disease mutations influence manganese accumulation and cytotoxicity.
Choi EK; Nguyen TT; Iwase S; Seo YA
FASEB J; 2019 Feb; 33(2):2228-2240. PubMed ID: 30247984
[TBL] [Abstract][Full Text] [Related]
17. Non-mutagenic Suppression of Enterocyte Ferroportin 1 by Chemical Ribosomal Inactivation via p38 Mitogen-activated Protein Kinase (MAPK)-mediated Regulation: EVIDENCE FOR ENVIRONMENTAL HEMOCHROMATOSIS.
Oh CK; Park SH; Kim J; Moon Y
J Biol Chem; 2016 Sep; 291(38):19858-72. PubMed ID: 27445333
[TBL] [Abstract][Full Text] [Related]
18. Non-HFE hepatic iron overload.
Pietrangelo A; Caleffi A; Corradini E
Semin Liver Dis; 2011 Aug; 31(3):302-18. PubMed ID: 21901660
[TBL] [Abstract][Full Text] [Related]
19. A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China.
Zhang W; Xu A; Li Y; Zhao S; Zhou D; Wu L; Zhang B; Zhao X; Wang Y; Wang X; Duan W; Wang Q; Nan Y; You H; Jia J; Ou X; Huang J;
Liver Int; 2019 Jun; 39(6):1120-1127. PubMed ID: 30500107
[TBL] [Abstract][Full Text] [Related]
20. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV.
Speletas M; Kioumi A; Loules G; Hytiroglou P; Tsitouridis J; Christakis J; Germenis AE
Blood Cells Mol Dis; 2008; 40(3):353-9. PubMed ID: 17997113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
